COVID-19 Vaccine Second Booster Authorization A ‘Stopgap Measure,’ US FDA’s Marks Says

 
• By Sue Sutter

CBER director says agency understands 'we simply can't be boosting people as frequently as we are,' but wants to give older and immunocompromised individuals extra protection now while FDA considers whether and when formulations should be modified ahead of an expected surge this fall.

COVID vaccine booster
A "stopgap measure" is how FDA's Peter Marks described the recent authorization of a second COVID-19 vaccine booster dose. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers